Kobayashi Pharmaceutical Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Kobayashi Pharmaceutical wird ein jährliches Gewinn- und Umsatzwachstum von 19% bzw. 3.7% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 19.1% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 8.1% betragen.

Wichtige Informationen

19.0%

Wachstumsrate der Gewinne

19.1%

EPS-Wachstumsrate

Personal Products Gewinnwachstum	19.7%
Wachstumsrate der Einnahmen	3.7%
Zukünftige Eigenkapitalrendite	8.1%
Analystenabdeckung	Good
Zuletzt aktualisiert	22 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Kobayashi Pharmaceutical's (TSE:4967) Soft Earnings Are Actually Better Than They Appear

Aug 21

Getting In Cheap On Kobayashi Pharmaceutical Co., Ltd. (TSE:4967) Is Unlikely

Aug 04

Investor Optimism Abounds Kobayashi Pharmaceutical Co., Ltd. (TSE:4967) But Growth Is Lacking

Apr 21

Estimating The Fair Value Of Kobayashi Pharmaceutical Co., Ltd. (TSE:4967)

Apr 03

Investors Met With Slowing Returns on Capital At Kobayashi Pharmaceutical (TSE:4967)

Feb 27

Gewinn- und Umsatzwachstumsprognosen

TSE:4967 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (JPY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	183,426	18,507	16,512	N/A	8
12/31/2025	175,952	17,420	9,934	N/A	8
12/31/2024	167,707	10,116	12,536	N/A	6
9/30/2024	168,799	10,184	N/A	N/A	N/A
6/30/2024	172,966	13,910	-10,824	16,636	N/A
3/31/2024	176,473	17,706	N/A	N/A	N/A
12/31/2023	173,455	20,338	4,791	18,360	N/A
9/30/2023	171,094	21,020	N/A	N/A	N/A
6/30/2023	168,619	20,186	1,429	20,341	N/A
3/31/2023	167,079	20,157	N/A	N/A	N/A
12/31/2022	166,258	20,022	15,685	31,914	N/A
9/30/2022	161,873	19,332	N/A	N/A	N/A
6/30/2022	159,464	19,534	23,864	31,465	N/A
3/31/2022	157,629	19,560	N/A	N/A	N/A
12/31/2021	155,252	19,715	18,234	22,419	N/A
9/30/2021	153,123	18,830	N/A	N/A	N/A
6/30/2021	151,386	18,868	18,003	21,790	N/A
3/31/2021	148,872	19,091	N/A	N/A	N/A
12/31/2020	150,514	19,205	19,837	23,986	N/A
9/30/2020	155,312	19,152	N/A	N/A	N/A
6/30/2020	160,602	19,155	20,133	24,786	N/A
3/31/2020	166,228	19,198	N/A	N/A	N/A
12/31/2019	168,052	19,139	15,285	20,089	N/A
9/30/2019	169,500	19,259	N/A	N/A	N/A
6/30/2019	168,431	18,596	16,735	20,861	N/A
3/31/2019	167,499	17,885	N/A	N/A	N/A
12/31/2018	167,479	18,023	16,306	20,007	N/A
9/30/2018	164,876	18,132	N/A	N/A	N/A
6/30/2018	162,132	16,455	N/A	19,577	N/A
3/31/2018	159,727	16,229	N/A	N/A	N/A
12/31/2017	156,761	15,863	N/A	22,350	N/A
12/31/2016	152,654	15,333	N/A	21,463	N/A
9/30/2016	148,008	15,561	N/A	18,058	N/A
6/30/2016	144,007	15,801	N/A	N/A	N/A
3/31/2016	137,211	13,466	N/A	14,329	N/A
12/31/2015	135,798	14,230	N/A	N/A	N/A
9/30/2015	133,385	13,008	N/A	15,474	N/A
6/30/2015	131,144	12,915	N/A	N/A	N/A
3/31/2015	128,344	12,448	N/A	15,445	N/A
12/31/2014	128,721	12,730	N/A	N/A	N/A
9/30/2014	127,574	11,808	N/A	14,931	N/A
6/30/2014	127,256	11,760	N/A	N/A	N/A
3/31/2014	127,293	12,307	N/A	13,513	N/A
12/31/2013	122,430	10,819	N/A	N/A	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 4967Das prognostizierte Gewinnwachstum (19% pro Jahr) liegt über der Sparquote (0.3%).

Ertrag vs. Markt: 4967Die Erträge des Unternehmens (19% pro Jahr) werden voraussichtlich schneller wachsen als der Markt JP (7.9% pro Jahr).

Hohe Wachstumserträge: 4967Die Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: 4967Die Einnahmen des Unternehmens (3.7% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt JP (4.2% pro Jahr).

Hohe Wachstumseinnahmen: 4967Die Einnahmen des Unternehmens (3.7% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 4967Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (8.1%).

Kobayashi Pharmaceutical Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 14%

Price target decreased by 8.3% to JP¥5,820

Consensus EPS estimates fall by 22%

Consensus EPS estimates fall by 12%

Price target decreased by 8.0% to JP¥6,348

Price target decreased by 16% to JP¥6,898

Recent updates

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 14%

Price target decreased by 8.3% to JP¥5,820

Kobayashi Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Nov 08, 2024

Kobayashi Pharmaceutical's (TSE:4967) Soft Earnings Are Actually Better Than They Appear

Consensus EPS estimates fall by 22%

Getting In Cheap On Kobayashi Pharmaceutical Co., Ltd. (TSE:4967) Is Unlikely

Kobayashi Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Aug 08, 2024

Upcoming dividend of JP¥44.00 per share

Consensus EPS estimates fall by 12%

Price target decreased by 8.0% to JP¥6,348

First quarter 2024 earnings: EPS misses analyst expectations

Price target decreased by 16% to JP¥6,898

Kobayashi Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on May 10, 2024

Investor Optimism Abounds Kobayashi Pharmaceutical Co., Ltd. (TSE:4967) But Growth Is Lacking

New minor risk - Share price stability

Estimating The Fair Value Of Kobayashi Pharmaceutical Co., Ltd. (TSE:4967)

Investor sentiment deteriorates as stock falls 18%

Investors Met With Slowing Returns on Capital At Kobayashi Pharmaceutical (TSE:4967)

Kobayashi Pharmaceutical Co., Ltd., Annual General Meeting, Mar 28, 2024

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Kobayashi Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Feb 09, 2024

Upcoming dividend of JP¥53.00 per share at 1.5% yield

New minor risk - Shareholder dilution

Kobayashi Pharmaceutical Co., Ltd. (TSE:4967) announces an Equity Buyback for 1,924,600 shares, representing 2.53% for ¥11,999.88 million.

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Kobayashi Pharmaceutical Co., Ltd. (TSE:4967) acquired Focus Consumer Healthcare, LLC.

Second quarter 2023 earnings: EPS exceeds analyst expectations

Upcoming dividend of JP¥39.00 per share at 1.1% yield

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Kobayashi Pharmaceutical Co., Ltd., Annual General Meeting, Mar 30, 2023

Upcoming dividend of JP¥47.00 per share

Kobayashi Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on May 10, 2023

Third quarter 2022 earnings: EPS exceeds analyst expectations

Third quarter 2022 earnings: EPS exceeds analyst expectations

Kobayashi Pharmaceutical Co., Ltd. (TSE:4967) announces an Equity Buyback for 1,265,800 shares, representing 1.64% for ¥9,999.82 million.

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of JP¥38.00 per share

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Upcoming dividend of JP¥44.00 per share

Third quarter 2021 earnings released: EPS JP¥89.58 (vs JP¥90.07 in 3Q 2020)

Second quarter 2021 earnings released: EPS JP¥54.41 (vs JP¥57.27 in 2Q 2020)

Upcoming dividend of JP¥35.00 per share

First quarter 2021 earnings released: EPS JP¥46.42 (vs JP¥47.87 in 1Q 2020)

Full year 2020 earnings released: EPS JP¥246 (vs JP¥244 in FY 2019)

Kobayashi Pharmaceutical Co., Ltd. to Report Q1, 2021 Results on Apr 27, 2021

New 90-day low: JP¥10,460

Kobayashi Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2021

Full year 2020 earnings released: EPS JP¥246 (vs JP¥244 in FY 2019)

Revenue and earnings miss expectations

Kobayashi Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Feb 01, 2021

New 90-day high: JP¥12,880

Upcoming Dividend of JP¥41.00 Per Share

New 90-day high: JP¥12,610

Kobayashi Pharmaceutical Co., Ltd. (TSE:4967) signed an contract to acquire Alva-Amco Pharmacal Companies, Inc. from Trusts all owned by the founder's family for approximately $110 million.

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken